Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01707953
Other study ID # RH-4074-OJ1
Secondary ID 2012-002572-13
Status Completed
Phase Phase 3
First received October 10, 2012
Last updated January 17, 2014
Start date October 2012
Est. completion date September 2013

Study information

Verified date January 2014
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Medicines AgencyDenmark: Danish Dataprotection Agency
Study type Interventional

Clinical Trial Summary

The aim of this study is to examine the efficacy of 5 mg Midodrine (Gutron) vs. placebo on reducing the incidence of orthostatic hypotension during mobilization 6 h after a total hip arthroplasty.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date September 2013
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Scheduled for primary unilateral hip arthroplasty

- Age >= 18 years

- Able to give informed consent

Exclusion Criteria:

- General anaesthesia for the current procedure

- Digoxin treatment.

- history of renal or hepatic failure

- history of glaucoma

- history chronic urinary retention requiring treatment

- history of orthostatic intolerance / hypotension

- other autonomous nervous system disease

- alcohol or drug abuse

- current malignant disease

- females in the fertile age (possible pregnancy or breast feeding)

- Treatment with anticoagulants

- BMI > 40 kg/m2

- Dementia or cognitive dysfunction (investigators evaluation)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Midodrine
Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).
Placebo
Placebo capsule to mimic midodrine

Locations

Country Name City State
Denmark Gentofte Hospital, Department of orthopaedic surgery Hellerup
Denmark Hvidovre Hospital, Department of orthopaedic surgery Hvidovre
Denmark Vejle Sygehus, Department of orthopedic surgery Vejle

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Haemodynamic response to mobilization 6 and 24 hours after surgery Haemodynamic response to mobilization (supine, sitting and standing):
Response in systolic and diastolic blood pressure
Response in heart rate.
Response in calculated haemodynamic variables (stroke volume, peripheral resistance)
6 and 24 hours after end of surgery No
Other Heart rate variability Heart rate variability measures including spectral analysis and LF/HF ratio at rest and during mobilization. before surgery, 6- and 24 hours after surgery No
Primary Orthostatic hypotension Orthostatic hypotension (OH) during early mobilization 6 hours after end of surgery. OH is classified according to international consensus. 6 hours after surgery No
Secondary Orthostatic hypotension 24 hours after surgery 24 hours after end of surgery. No
Secondary Orthostatic Intolerance Orthostatic intolerance is defined as subjective presyncopal symptoms (dizziness, nausea etc.) during mobilization after surgery 6 and 24 hours after end of surgery No
Secondary Treatment side effects The following side effects to Midodrine are evaluated:
Pruritus
Headache
Supine hypertension
Urinary retention
6 and 24 hours after end of surgery Yes